Hypofractionated radiotherapy as salvage for rising prostate-specific antigen after radical prostatectomy

被引:19
作者
Lee, LW
McBain, CA
Swindell, R
Wylie, JP
Cowan, RA
Logue, JP [1 ]
机构
[1] Christie Hosp, Dept Clin Oncol, Manchester M20 4BX, Lancs, England
[2] Christie Hosp, Dept Med Stat, Manchester, Lancs, England
关键词
prostate cancer; radical prostatectomy; radiotherapy; salvage;
D O I
10.1016/j.clon.2004.07.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims: To review the outcome of men receiving hypofractionated salvage radiotherapy for rising prostate-specific antigen (PSA) after radical prostatectomy. Materials and methods: A. retrospective analysis of 61 men referred for salvage radiotherapy for biochemical relapse after radical prostatectorny was conducted. Twenty-four men receiving hormonal therapy or with follow-up of less than 12 months were excluded. Thirty-seven men were identified, median age 64 years, median preoperative PSA 11 ng/ml (5.6-60 ng/ml), Gleason scores < 7: 70%, Gleason scores greater than or equal to 7: 30%. Twenty-seven men had positive surgical resection margins, eight had seminal-vesicle involvement and one had lymph-node involvement. Diagnosis of failure after radical prostatectomy was made on rising PSA in all cases; 19 men also had positive magnetic resonance imaging, 11 abnormal digital rectal examination and nine positive biopsy. Radiotherapy was delivered conformally to the prostatic fossa, 50-52.5 Gy in 20 fractions over 4 weeks. Date of failure after radiotherapy was defined by the American Society for Therapeutic Radiology and Oncology (ASTRO) consensus criteria or as date of commencement of hormonal therapy for rising PSA. Results: Median time front radical prostatectorny to radiotherapy was 30.6 months (8-68 months); median pre-radiotherapy PSA was 2.9 ng/ml (0.5-11.4 ng/ml). PSA response after radiotherapy was seen in 33 out of 37 (89%) patients. At median follow-up of 36 months (20-85 months), 28 out of 37 remained disease-free. Thirteen more patients have had two consecutive PSA rises. Actuarial 3-year disease-free survival is 74%. No patient has developed metastases or died of prostate cancer. Pre-radiotherapy PSA less than 2 ng/ml predicted disease-free survival (P = 0.027). No acute toxicity greater than Radiation Therapy Oncology Group (RTOG) G2 was observed. Conclusions: Salvage radiotherapy after radical prostatectomy achieved durable biochemical control in most patients. Outcome is improved if radiotherapy is delivered when PSA is less than 2 ng/ml. A policy of close monitoring after radical prostatectomy with early referral for salvage radiotherapy is advocated. (C) 2004 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:517 / 522
页数:6
相关论文
共 50 条
[31]   Management of Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy: A Systematic Review of the Literature [J].
Ploussard, Guillaume ;
Fossati, Nicola ;
Wiegel, Thomas ;
D'Amico, Anthony ;
Hofman, Michael S. ;
Gillessen, Silke ;
Mottet, Nicolas ;
Joniau, Steven ;
Spratt, Daniel E. .
EUROPEAN UROLOGY ONCOLOGY, 2021, 4 (02) :150-169
[32]   Prospective assessment of gastrointestinal and genitourinary toxicity of salvage radiotherapy for patients with prostate-specific antigen relapse or local recurrence after radical prostatectomy [J].
Pearse, Maria ;
Choo, Richard ;
Danjoux, Cyril ;
Gardner, Sandra ;
Morton, Gerard ;
Szumacher, Ewa ;
Lorlaw, Andrew ;
Cheung, Patrick .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (03) :792-798
[33]   Salvage Radiation in Men After Prostate-Specific Antigen Failure and the Risk of Death [J].
Cotter, Shane E. ;
Chen, Ming Hui ;
Moul, Judd W. ;
Lee, W. Robert ;
Koontz, Bridget F. ;
Anscher, Mitchell S. ;
Robertson, Cary N. ;
Walther, Philip J. ;
Polascik, Thomas J. ;
D'Amico, Anthony V. .
CANCER, 2011, 117 (17) :3925-3932
[34]   Prostate-Specific Membrane Antigen PET/Magnetic Resonance Imaging for the Planning of Salvage Radiotherapy in Patients with Prostate Cancer with Biochemical Recurrence After Radical Prostatectomy [J].
Elschot, Mattijs ;
Selnaes, Kirsten Margrete ;
Langorgen, Sverre ;
Johansen, Hakon ;
Bertilsson, Helena ;
Tandstad, Torgrim ;
Bathen, Tone Frost .
PET CLINICS, 2019, 14 (04) :487-+
[35]   Evaluation and management of prostate-specific antigen recurrence after radical prostatectomy for localized prostate cancer [J].
Naito, S .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2005, 35 (07) :365-374
[36]   Intensifying Salvage Therapy in Prostate-specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy with Apalutamide, Salvage Radiation, and Docetaxel: The Phase 2 STARTAR Trial [J].
Zhang, Tian ;
Howard, Lauren ;
Koontz, Bridget F. ;
Tagawa, Scott T. ;
Nagar, Himanshu ;
Bitting, Rhonda L. ;
Frizzell, Bart A. ;
Nordquist, Luke ;
Rasmussen, Julia ;
Riggan, Colleen ;
Reyes, Marco ;
Davies, Catrin ;
Gray, Steven R. ;
Newman, Carly R. ;
Fernandez, Escarleth ;
Ramalingam, Sundhar ;
Harrison, Michael R. ;
George, Daniel J. ;
Wu, Yuan ;
Armstrong, Andrew J. .
EUROPEAN UROLOGY ONCOLOGY, 2025, 8 (02) :287-295
[37]   Prostate-specific antigen (PSA) bounce following salvage radiotherapy to the prostate bed in a patient with prostate cancer post-prostatectomy [J].
Rowe, Michael ;
Adamson, Ellis ;
McGrane, John .
INTERNATIONAL CANCER CONFERENCE JOURNAL, 2020, 9 (04) :217-220
[38]   Prostate-specific antigen (PSA) bounce following salvage radiotherapy to the prostate bed in a patient with prostate cancer post-prostatectomy [J].
Michael Rowe ;
Ellis Adamson ;
John McGrane .
International Cancer Conference Journal, 2020, 9 :217-220
[39]   Salvage Radiation Therapy for Increasing Prostate-Specific Antigen After Radical Prostatectomy: Who, When, and How? Reply [J].
Pisansky, Thomas M. ;
Stish, Bradley J. .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04) :470-+
[40]   Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes [J].
Preisser, Felix ;
Chun, Felix K. H. ;
Pompe, Raisa S. ;
Heinze, Alexander ;
Salomon, Georg ;
Graefen, Markus ;
Huland, Hartwig ;
Tilki, Derya .
EUROPEAN UROLOGY, 2019, 76 (01) :106-114